Microsurgical treatment of craniopharyngiomas: report of 284 patients
- PMID: 17042979
Microsurgical treatment of craniopharyngiomas: report of 284 patients
Abstract
Background: Generally, total surgical removal of craniopharyngioma results in satisfactory outcome with a low recurrence rate, however, the location of the tumor and its adherence to the hypothalamic structures can make the operation difficult. The goal of the present study was to assess the outcome of craniopharyngiomas in 284 patients treated surgically.
Methods: A total of 284 patients (151 men and 133 women) with craniopharyngioma were treated surgically by our neurosurgeons from January 1996 to March 2006. Among them, 226 (79.6%) patients were adults (15 years of age or older; mean, 35.8 +/- 10.6), 58 (20.4%) were children (14 years of age or younger; mean, 9.1 +/- 3.8). The diameter of the tumors were 2.0 - 9.0 cm (mean, 36.54 +/- 11.4). The tumors were classified into the superior (23 patients) and inferior ventricular (261) types according to the location of the tumor relative to the third ventricular floor. For the patients with craniopharyngioma of inferior ventricular type, pterional approach was used in 191 (67.3%) patients, subfrontal approach in 17 (6.0%), and translamina terminalis through frontobasal interhemispheric approach in 53 (18.7%). For those with the tumors of superior ventricular type, transcallosal approach into the anterior third ventricle was done in 10 (3.5%) patients, and the lamina terminalis approach in 13 (4.6%). Of the 284 patients, 204 (71.8%) were followed up for 0.5 to 8 years (mean, 2.1 +/- 1.8), including 162 patients received total tumor removal, and 37 underwent subtotal or partial removal.
Results: Total, subtotal and partial removal of the tumors were achieved in 237 (83.5%), 34 (12.0%) and 13 (4.5%) patients, respectively. The pituitary stalk was preserved in 176 (62.0%) patients, severed in 52 (18.3%), and unidentified in 56 (19.7%). Twelve (4.2%) patients died within one month after the surgery. During the follow-up, 23 (14.1%) patients experienced tumor recurrence 1.0 - 3.5 years (mean, 1.8 +/- 1.6) after total tumor removal, and 24 (64.9%) had recurrent tumor 0.25 - 1.5 years (mean, 0.5 +/- 0.4) after subtotal or partial resection. Normal activities of daily living were regained in 63 (80%) patients, independence in 29 (14.2%), and daily life with assistance in 9 (4.4%). Four (2.0%) patients died 0.9 - 3 years (mean, 1.6 +/- 1.4) after discharge from hospital, 3 of them died of hypothalamic deficiency.
Conclusions: We can protect the hypothalamic structures and its perforating arteries by choosing surgical approaches according to the location of craniopharygioma relative to the third ventricular floor. The mortality, morbidity, and recurrence rate in patients received total resection are lower than those of patients underwent subtotal or partial resections. In addition, preservation of the pituitary stalk is critical when total tumor resection is feasible.
Similar articles
-
[Microsurgical resection of the recurrent craniopharyngiomas].Zhonghua Wai Ke Za Zhi. 2004 Jul 7;42(13):769-72. Zhonghua Wai Ke Za Zhi. 2004. PMID: 15363291 Chinese.
-
Craniopharyngioma: surgical experience of 309 cases in China.Clin Neurol Neurosurg. 2008 Feb;110(2):151-9. doi: 10.1016/j.clineuro.2007.10.013. Epub 2007 Dec 3. Clin Neurol Neurosurg. 2008. PMID: 18063470
-
[Experience in surgical treatment of 110 patients with craniopharyngiomas].Zhonghua Wai Ke Za Zhi. 2001 Aug;39(8):608-10. Zhonghua Wai Ke Za Zhi. 2001. PMID: 11758199 Chinese.
-
Craniopharyngiomas in children.Pediatr Neurosurg. 2007;43(4):265-78. doi: 10.1159/000103306. Pediatr Neurosurg. 2007. PMID: 17627142 Review.
-
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up.Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409. doi: 10.1111/j.1365-2265.2005.02231.x. Clin Endocrinol (Oxf). 2005. PMID: 15807869 Review.
Cited by
-
Radiological and endocrinological evaluations with grading of hypothalamic perifocal edema caused by craniopharyngiomas.Pituitary. 2019 Apr;22(2):146-155. doi: 10.1007/s11102-019-00945-z. Pituitary. 2019. PMID: 30847775
-
Magnetic resonance imaging as predictor of functional outcome in craniopharyngiomas.Endocrine. 2016 Jan;51(1):148-62. doi: 10.1007/s12020-015-0683-x. Epub 2015 Jul 16. Endocrine. 2016. PMID: 26179178
-
Craniopharyngioma and the Third Ventricle: This Inescapable Topographical Relationship.Front Oncol. 2022 Mar 22;12:872689. doi: 10.3389/fonc.2022.872689. eCollection 2022. Front Oncol. 2022. PMID: 35392218 Free PMC article. No abstract available.
-
Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.J Neurooncol. 2011 Feb;101(3):463-76. doi: 10.1007/s11060-010-0265-y. Epub 2010 Jun 10. J Neurooncol. 2011. PMID: 20535527 Free PMC article.
-
Early outcome in endoscopic extended endonasal approach for removal of supradiaphragmatic craniopharyngiomas: a case series and a comprehensive review.Radiol Oncol. 2013 Jul 30;47(3):266-79. doi: 10.2478/raon-2013-0036. eCollection 2013. Radiol Oncol. 2013. PMID: 24133392 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical